27
Participants
Start Date
April 28, 2017
Primary Completion Date
May 31, 2017
Study Completion Date
May 31, 2017
Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%
"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)
"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
DermIng S.r.l. Single Member Company, Monza
Lead Sponsor
Derming SRL
OTHER